May 19 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...